• English
  • Français
  • Español
  • Facebook
  • RSS
  • Twitter

Therapeutics Initiative

Independent Healthcare Evidence

  • TI
  • About Us
    • Oversight Committee
    • Steering Committee
    • Working Groups
      • Drug Assessment
      • Education
      • PharmacoEpidemiology
      • Cochrane Hypertension
    • Members
    • TI Surveys
    • Questions & Answers
  • Therapeutics Letter
  • Our Evidence Reviews
  • Portrait
  • Continuing Education
  • Contact Us
  • Subscribe
Home > Archives for pharmacoepidemiology

Effectiveness and Safety among Direct Oral Anticoagulants in Non Valvular Atrial Fibrillation: A Multi‐Database Cohort Study with Meta‐Analysis

November 30, 2020 PharmacoEpidemiology

British Journal of Clinical Pharmacology, November 2020 Madeleine Durand, Mireille E. Schnitzer, Menglan Pang, Greg Carney, Sherif Eltonsy, Kristian B. Filion, Anat Fisher, Min Jun, I. fan Kuo, Alexis Matteau, J. Michael Paterson, Jacqueline Quail, Christel Renoux for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators Abstract Background: There are conflicting … [Read more...]

Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

October 1, 2020 PharmacoEpidemiology

The Journal of Rheumatology, October 2020 Anat Fisher, Marie Hudson, Robert W. Platt and Colin R. Dormuth for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators Abstract Objective: To compare medication persistence of tofacitinib with persistence of injectable biological disease-modifying antirheumatic drugs (bDMARD) in patients with rheumatoid … [Read more...]

Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study

August 25, 2020 PharmacoEpidemiology

Diabetes Care Aug 2020, dc200267; DOI: 10.2337/dc20-0267 Oriana Hoi Yun Yu, Sophie Dell’Aniello, Baiju R. Shah, Vanessa C. Brunetti, Jean-Marc Daigle, MichaelFralick, Antonios Douros, Nianping Hu, Silvia Alessi-Severini, Anat Fisher, Shawn C. Bugden, Paul E.Ronksley, Kristian B. Filion, Pierre Ernst, Lisa M. Lix for the Canadian Network for Observational Drug Effect Studies (CNODES) … [Read more...]

Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

September 23, 2020 PharmacoEpidemiology

BMJ 2020; 370 DOI: https://doi.org/10.1136/bmj.m3342 (Published 23 September 2020) Kristian B Filion, Lisa M Lix, Oriana HY Yu, Sophie Dell’Aniello, Antonios Douros, Baiju R Shah, Audray St-Jean, Anat Fisher, Eric Tremblay, Shawn C Bugden, Silvia Alessi-Severini, Paul E Ronksley, Nianping Hu, Colin R Dormuth, Pierre Ernst, Samy Suissa, on behalf of the Canadian Network for Observational Drug … [Read more...]

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

July 28, 2020 PharmacoEpidemiology

Annals of Internal Medicine 2020 July 28. DOI: 10.7326/M20-0289 Antonios Douros, MD, PhD; Lisa M. Lix, PhD; Michael Fralick, MD, PhD; Sophie Dell’Aniello, MSc; Baiju R. Shah, MD, PhD; Paul E. Ronksley, PhD; Eric Tremblay, BPharm, MSc; Nianping Hu, PhD; Silvia Alessi-Severini, PhD; Anat Fisher, MD, PhD; Shawn C. Bugden, PharmD, MSc; Pierre Ernst, MD, MSc; and Kristian B. Filion, PhD; for the … [Read more...]

Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia—An interim report

June 1, 2020 PharmacoEpidemiology

Pharmacoepidemiol Drug Saf. 2020;1–8. First published: 28 May 2020. Fisher A, Kim JD, Dormuth CR Purpose: We explored changes in health services utilization associated with the Biosimilars Initiative introduced in British Columbia on May 27, 2019. To maintain drug coverage, the policy requires users of originator infliximab or etanercept to transition to biosimilar versions. We present a … [Read more...]

Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study

May 13, 2020 PharmacoEpidemiology

First published: 08 May 2020 Abstract AIMS The United States Food and Drug Administration has warned of an increased risk of serious urinary tract infection (UTI) and Fournier’s gangrene in patients with diabetes mellitus type 2 treated with sodium–glucose cotransporter 2 inhibitors (SGLT2i). However, evidence on these risks is limited. We aimed to compare urosepsis rates in SGLT2i users with … [Read more...]

Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators

April 30, 2020 PharmacoEpidemiology

BMJ 2020; 369:m1107 (Published 29 April 2020) DOI: https://doi.org/10.1136/bmj.m1107 Key messages Sodium glucose co-transporter-2 (SGLT2) inhibitors came to market amid heightened concern over the safety of diabetes drugs The drugs have received several serious safety warnings since approval, but the number, timeliness, and strength of these safety communications have differed … [Read more...]

New Publications from the TI PharmacoEpidemiology Group

January 10, 2020 News Leave a Comment

Share

We are highlighting 4 recent articles published by members of the PharmacoEpidemiology Group (PEG) of the Therapeutics Initiative: Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study Comparison of cholinesterase … [Read more...]

Identifying sequential episodes of pharmacotherapy as a method for assessing treatment failure in comparative effectiveness research

January 10, 2020 PharmacoEpidemiology

Carney, G, Maclure, M, Bassett, K, Taylor, S, Dormuth, CR Pharmacoepidemiol Drug Saf. 2019; 1– 9. https://doi.org/10.1002/pds.4926 Abstract Purpose To describe and implement a novel method of measuring comparative effectiveness using sequential episodes of pharmacotherapy as a proxy for treatment failure. Methods Retrospective cohort study using linked deidentified data from the British … [Read more...]

  • 1
  • 2
  • Next Page »
  • About Us
    • Oversight Committee
    • Questions & Answers
    • Steering Committee
    • Working Groups
      • Drug Assessment
      • Education
      • PharmacoEpidemiology
      • Cochrane Hypertension
    • Members
    • TI Surveys
  • Portrait
    • Frequently Asked Questions
    • Portrait Contact
  • Therapeutics Letter
  • Our Evidence Reviews
  • Get Involved
  • Continuing Education
    • Best Evidence
  • Contact Us
  • Terms & Policies
    • Legal Information & Terms of Use
    • Privacy Policy
    • Acceptable Use Policy

Categories

  • News (123)
  • Therapeutics Letter (133)
  • Portrait (1)
  • Drug Assessments (39)
  • PharmacoEpidemiology (75)
  • Podcasts & Videos (50)

Recent Seminars

Dr. Jessica Otte: We Need To Talk About Tramadol

Share

[Feb 10] Therapeutics Initiative Best Evidence Webinar: Sex and Post-SSRI Evidence-based Medicine Dysfunction

Register
Share

[Mar 10] Therapeutics Initiative Virtual Workshop – Using Evidence in Shared Decision Making: A Case-based, Critical Appraisal Approach for Busy Clinicians

Register
Share

Therapeutics Initiative

Our mission is to provide physicians, nurse practitioners, pharmacists, allied health professionals, and the public with up-to-date, independent, evidence-based, practical information on healthcare interventions. Read more Donate

Contact

2176 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3
Contact us
Office: +1 604-822-0700
Fax: +1 604-822-0701

UBC logoISDB logo

Subscribe

Subscribe to receive email notifications from the TI about the Therapeutics Letter, upcoming educational events, personal prescribing portraits and other news and recent publications. SUBSCRIBE

© 1994 - 2021 Therapeutics Initiative · Terms & Policies · TM